Literature DB >> 264199

The pharmacology and subacute toxicology of dopamine.

J F Zaroslinski, L H Possley, R A Schwartz, R N Morris, F A Carone, R K Browne.   

Abstract

Preclinical studies with dopamine showed a unique spectrum of biological activities which suggested that it might be of therapeutic use in the clinical syndromes of shock and low cardiac output. Most prominent among these were its effects on cardiac output, renal perfusion, and vital organ flow. The unique effect on renal function and the subsequent studies by Goldberg and his colleagues led to the recognition of a previously unknown catecholamine receptor site, the 'dopaminergic receptor'. Studies on the toxicology of dopamine in our laboratories suggested that dopamine could be safely used in the clinic.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 264199      PMCID: PMC1543337     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


  9 in total

1.  A PROPOSED MECHANISM FOR THE DEPRESSOR EFFECT OF DOPAMINE IN THE ANESTHETIZED DOG.

Authors:  J N EBLE
Journal:  J Pharmacol Exp Ther       Date:  1964-07       Impact factor: 4.030

2.  REGULATION OF PROSTATE SECRETION IN THE RAT.

Authors:  W E FARNSWORTH; M H LAWRENCE
Journal:  Proc Soc Exp Biol Med       Date:  1965-06

3.  Indirect sympathomimetic actions of dopamine.

Authors:  J B Farmer
Journal:  J Pharm Pharmacol       Date:  1966-04       Impact factor: 3.765

4.  Myocardial hypertrophy resulting from low dosage isoproterenol administration in rats.

Authors:  E L Alderman; D C Harrison
Journal:  Proc Soc Exp Biol Med       Date:  1971-01

5.  The potential role of dopamine in the treatment of shock.

Authors:  L I Goldberg; R C Talley; J L McNay
Journal:  Prog Cardiovasc Dis       Date:  1969-07       Impact factor: 8.194

6.  Effects of dopamine and alpha-methyl-dopamine on smooth muscle and on the cardiac pacemaker.

Authors:  T H Tsai; S Z Langer; U Trendelenburg
Journal:  J Pharmacol Exp Ther       Date:  1967-05       Impact factor: 4.030

7.  Dopamine in the treatment of hypotension and shock.

Authors:  K L MacCannell; J L McNay; M B Meyer; L I Goldberg
Journal:  N Engl J Med       Date:  1966-12-22       Impact factor: 91.245

8.  Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow.

Authors:  J L McNay; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1966-01       Impact factor: 4.030

9.  Effects of dopamine on sinus rate and ventricular contractile force of the dog heart in vitro and in vivo.

Authors:  M Endoh
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

  9 in total
  6 in total

1.  Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells.

Authors:  Debanjan Chakroborty; Chandrani Sarkar; Hongmei Yu; Jiang Wang; Zhongfa Liu; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity.

Authors:  Jin Wu; Ruihua Zhang; Ning Tang; Zizhen Gong; Jiefei Zhou; Yingwei Chen; Kang Chen; Wei Cai
Journal:  J Leukoc Biol       Date:  2014-10-23       Impact factor: 4.962

3.  Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization.

Authors:  Debanjan Chakroborty; Uttio Roy Chowdhury; Chandrani Sarkar; Rathindranath Baral; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

4.  Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects.

Authors:  U Gundert-Remy; J Penzien; R Hildebrandt; W Mäurer; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Dopamine D2 receptor signalling controls inflammation in acute pancreatitis via a PP2A-dependent Akt/NF-κB signalling pathway.

Authors:  Xiao Han; Bin Li; Xin Ye; Tunike Mulatibieke; Jianghong Wu; Juanjuan Dai; Deqing Wu; Jianbo Ni; Ruling Zhang; Jing Xue; Rong Wan; Xingpeng Wang; Guoyong Hu
Journal:  Br J Pharmacol       Date:  2017-10-29       Impact factor: 8.739

6.  Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.

Authors:  Luke H Hoeppner; Ying Wang; Anil Sharma; Naureen Javeed; Virginia P Van Keulen; Enfeng Wang; Ping Yang; Anja C Roden; Tobias Peikert; Julian R Molina; Debabrata Mukhopadhyay
Journal:  Mol Oncol       Date:  2014-08-30       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.